Interstitial granulomatous dermatitis associated with darifenacin.
Author(s): Mason HR, Swanson JK, Ho J, Patton TJ
Affiliation(s): Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Publication date & source: 2008-09, J Drugs Dermatol., 7(9):895-7.
Publication type: Case Reports
Interstitial granulomatous dermatitis is most commonly associated with rheumatoid arthritis (RA) but may be induced by medications as well. Darifenacin is a muscarinic antagonist which was FDA approved for the treatment of overactive bladder in December 2004. The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.
|